Cure8 research brief
The study describes a new oral nanotherapy that delivered apremilast to the inflamed colon in mice and reportedly reduced gut inflammation and behaviors resembling anxiety/depression—suggesting a combined microbiota–gut–brain target that could be relevant for IBD patients with psychiatric comorbidity.
Researchers, translational scientists, and clinicians focused on IBD therapeutics, microbiome interventions, and gut–brain axis research.
This paper reports preclinical (animal-model) research testing βG@Apr-WPG nanomicelles — a β-glucan–coated, apremilast-containing nanoparticle designed for gastroprotection, sustained and inflammation-responsive drug release, and modulation of the microbiota–gut–brain axis.
In mice with chemically induced colitis the authors report improved gut barrier integrity, reduced histologic inflammation, changes in microbiota composition, lower systemic and neuroinflammation markers, and reductions in anxiety- and depression-like behaviors compared with free apremilast.
The study is preclinical: findings come from laboratory and mouse experiments, not human trials. Safety and efficacy in people are not established.
Results are from preclinical mouse experiments (abstract-level summary). This does not constitute evidence of safety or efficacy in humans; clinical testing would be needed.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study identifies a gut bacteria–liver signaling axis (Lactobacillus johnsonii → hepatic LXRα–SCD1) that may explain how altered hepatic lipids contribute to UC and related liver injury, and shows pristimerin can...
Mitochondrial dysfunction may be a central contributor to UC inflammation and is being targeted by new therapeutic strategies that could lead to different treatment approaches in the future.
The article explains how gut bacteria may contribute to IBD and summarizes common tests and treatments people are likely to encounter. It highlights emerging microbial therapies (probiotics and FMT) that some patients...
